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We previously determined that the predicted risk of radiogenic second cancer in the bladder and
rectum after proton arc therapy (PAT) was less than or equal to that after volumetric modulated
arc therapy (VMAT) with photons, but we did not consider the impact of margin size on that risk.
The current study was thus conducted to evaluate margin size’s effect on the predicted risks of
second cancer for the two modalities and the relative risk between them. Seven treatment plans
with margins ranging from 0 mm in all directions to 6 mm posteriorly and 8 mm in all other
directions were considered for both modalities. We performed risk analyses using three risk
models with varying amounts of cell sterilization and calculated ratios of risk for the
corresponding PAT and VMAT plans. We found that the change in risk with margin size
depended on the risk model but that the relative risk remained nearly constant with margin size,
regardless of the amount of cell sterilization modeled. We conclude that while margin size
influences the predicted risk of a second cancer for a given modality, it appears to affect both
modalities in roughly equal proportions so that the relative risk between PAT and VMAT is
approximately equivalent.

second cancer; second malignant neoplasm; volumetric modulated arc therapy; VMAT; proton arc
therapy; proton therapy; prostate cancer; margin size

1. Introduction
Long-term cancer survivors who received radiotherapy are at an increased risk to develop a
radiogenic second cancer (Friedman et al 2010). For prostate cancer patients, the risk of
second cancer incidence is a public health concern because of the large population of
survivors: 2.3 million in the United States in 2007 (SEER). Previous studies have reported a
lower predicted risk of radiogenic second cancer after proton radiotherapy than after
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intensity-modulated radiotherapy for cancers at various anatomic sites (Miralbell et al 2002,
Newhauser et al 2009, Taddei et al 2010), including the prostate (Schneider et al 2006,
Schneider et al 2007, Fontenot et al 2009). The decreased predicted risk for proton therapy
was persevered even when stray neutron dose was considered in the risk calculations
(Fontenot et al 2009). Moreover, the advantage for proton therapy was shown to be
independent of the uncertainty in the mean radiation weighting factor for neutrons
(Newhauser et al 2009, Fontenot et al 2010).
Because of arc therapies’ potential for increased conformity and speed of delivery, interest
in their use has increased in recent years. For example, proton arc therapy (PAT) has
appeared in the literature (Isacsson et al 1997, Deasy et al 1997, Sandison et al 1997, Oelfke
and Bortfeld 2000, Flynn et al 2007), and machines capable of delivery of PAT have been
proposed (Caporaso et al 2008, Sengbusch et al 2009). Additionally, the rotational version
of intensity-modulated radiotherapy, volumetric modulated arc therapy (VMAT), has
become widely available since its proposal in 2008 (Otto 2008). Furthermore, several
authors have reported on the use of VMAT for prostate cancer (Palma et al 2008, Zhang et
al 2009, Wolff et al 2009, Kjaer-Kristoffersen et al 2009, Yoo et al 2010), and this technique
is routinely used at many radiotherapy centers.
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Advanced prostate radiotherapy techniques like proton therapy and VMAT often utilize
image-guidance for setup. Image-guidance has facilitated a reduction in margins around the
prostate. For example, Balter et al (1993) found that when setup errors exceed 1 cm,
correction with portal imaging reduced the necessary margin by 6 mm. In one retrospective
study, ultrasound guidance reduced the necessary margin to 4 mm or less (Keller et al 2004).
In another retrospective study, prostate margins were reduced from 10 mm to 5 mm with
ultrasound or CT alignment (Schaly et al 2005). While margin sizes are institution- and
technique-specific, we expect that margins will generally continue to decrease as
immobilization and image-guidance techniques evolve.
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Recently, we compared the predicted risk of radiogenic second cancer incidence in the
bladder and rectum after PAT for prostate cancer to that after 6-MV VMAT. We reported
that the ratio of excess relative risk (RRR) between the two modalities (PAT:VMAT) was
approximately 1 when predicted with the linear-non-threshold risk model and was
significantly less than 1 (interval: 0.74–0.91) when predicted with the linear-exponential and
linear-plateau risk models (Rechner et al 2012). However, the literature does not contain any
reports of the effect of margin size on the risk of radiogenic second cancer following
rotational radiotherapy with protons versus photons, and we did not investigate the effect of
margin size in our previous work. As mentioned above, margin size is an important variable
because margins are institution-specific and will most likely decrease with advances in
imaging and patient immobilization.
Therefore, the aim of this work was to quantify the influence of margin size on the predicted
RRR of radiogenic second cancer incidence in the bladder and rectum after PAT for prostate
cancer versus 6-MV VMAT. To accomplish this goal, we created treatment plans using
various margin sizes and then applied risk models from the literature to dosimetric data from
the treatment planning system (TPS) and from Monte Carlo simulations.

2. Materials and Methods
2.1 Patient selection and contouring
This work was performed under an institutional review board-approved protocol for
retrospective treatment planning studies. Dosimetric calculations and risk predictions were
carried out on the simulation computed tomography (CT) dataset for a previously studied
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patient treated at our institution for prostate cancer. This patient, a 56 year old man with
stage T2a adenocarcinoma of the prostate, was representative of the patients commonly seen
in our clinic (Fontenot et al 2009, Rechner et al 2012). A water-filled balloon had been
inserted into the patient’s rectum during simulation and treatment to provide localization,
immobilization, and rectal sparing, and the balloon was visible on the simulation images.
The CTV was defined as the prostate and proximal seminal vesicles.
For the current analysis, we created multiple planning target volumes (PTVs) by adding
various margins to the CTV. The prevailing standard-of-care (SOC) at our institution was a
5-mm margin in the posterior direction and a 7-mm margin in all other directions. In this
study, we investigated seven margin sizes, ranging from the theoretical limit of no margin
(CTV=PTV) to margins slightly larger than our current SOC: 6 mm in the posterior
direction and 8 mm in all other directions. A complete list of margin designs is presented in
table 1.
2.2 Treatment planning and calculation of therapeutic and stray dose
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Treatment plans were created for each PTV for proton and photon treatments using a
commercial TPS (Eclipse, Varian Medical Systems, Palo Alto, CA; version 8.6.15 for
VMAT and version 8.9.08 for proton therapy). The treatment planning method was
consistent with that used in our previous study (Rechner et al 2012). For proton therapy, 16
static passively scattered beams were used to approximate arc delivery, which is similar to
the approach used by Flynn et al (2007). The lateral, proximal, and distal proton beam
margins were calculated for the SOC PTV with a method used clinically at our institution
(Moyers et al 2001). Then, the differences between the new CTV-to-PTV margins and the
SOC CTV-to-PTV margins (4th and 5th columns in table 1) were applied to the SOC lateral,
proximal, and distal proton beam margins to produce high-dose regions that provided
appropriate coverage for the new PTVs. For VMAT, each two-arc plan was created by
applying all the same objectives in the inverse treatment planning process. Specifically, the
same objective that was applied to the SOC PTV was applied to each new PTV. The aim of
this treatment planning method was to produce comparable plans except for the volume of
the high-dose region. For consistency and adequate target coverage, all treatment plans were
prescribed a mean dose of 76 gray (Gy (RBE) [relative biological effectiveness] for protons
(ICRU 2007)]) to the PTV, each normalized identically so that all plans provided for at least
99% of the PTV to receive the prescribed dose.
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Both therapeutic and stray contributions to dose were considered. Therapeutic dose was
obtained by exporting the differential dose volume histograms (DVHs) from the TPS for
each organ and each treatment plan considered. Stray dose was calculated with Monte Carlo
simulations according to our previous method (Newhauser et al 2007, Rechner et al 2012)
for PAT. For VMAT, stray dose based on the treatment plan for the SOC PTV was
estimated following the method of Howell et al (2010a, 2010b). While proton and photon
doses reported in Gy (RBE) and Gy, respectively, are numerically equivalent to those
reported in sieverts (Sv) (ICRP 1991, ICRU 2007), one must convert the neutron absorbed
dose in Gy to an equivalent dose in Sv by applying a fluence-weighted average radiation
weighting factor for neutrons (ICRP 2003, Fontenot et al 2008). The equivalent dose
calculations were described in detail in our previous study (Rechner et al 2012).
2.3 Risk prediction
The quantity excess relative risk (ERR) was chosen to describe the predicted risk of
radiogenic second cancer incidence in this study. Three general forms of risk models were
applied to calculate the predicted ERR: the linear-non-threshold risk model (NRC 2006), the
linear-exponential risk model (Fontenot et al 2010, Fontenot et al 2009), and the linear-
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plateau risk model (Fontenot et al 2010, Fontenot et al 2009). Additionally, for the linearexponential and linear-plateau risk models, both low- and high-dose inflection points (which
indicate the maximum risk for cancer induction) of 10 and 40 Sv, respectively, were
investigated. The risk of radiogenic second cancers in the bladder wall and rectal wall were
summed to yield the total ERR for the modality.
The ratio of excess relative risk (RRR) was calculated to compare the two modalities.
Specifically, the ratio of ERR values was taken with VMAT as the reference:
(1)

Therefore, an RRR value less than unity would indicate an advantage for PAT, and an RRR
value greater than unity would indicate an advantage for VMAT. A linear regression
analysis was performed to quantify the potential relationship between risk and margin size.

3. Results
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Sample treatment plans for PAT and VMAT are shown in figures 1 and 2, respectively. As
anticipated, the distribution of low dose (i.e. 10 Gy (RBE) or Gy) was similar for each
margin size for a given modality, while the volume of the high-dose region expanded as the
CTV-to-PTV margin size increased. Because of the steep dose gradients in the bladder and
rectal walls, the minimum and maximum doses to the bladder and rectal walls remained
nearly constant. In contrast, the mean doses to the bladder and rectal walls increased as the
gradient further overlapped these organs (tables 2 and 3). Furthermore, it can be seen in
figures 3 and 4 that the volume that received any given dose generally increased with
increasing margin size.
The increase in mean dose generally translated into an increase in risk, but the amount of
increase depended on the risk model (figure 5). Unsurprisingly, the increase in ERR with
margin size was greatest for the linear-non-threshold model and least for the risk models that
accounted for cell killing. Specifically, when a linear regression was performed on risk from
the linear-non-threshold model, the ERR increased approximately 0.41 (5.9%) and 0.35
(5.2%) per millimeter increase in margin for PAT and VMAT, respectively. The linearexponential risk model with an inflection point at 10 Sv showed virtually no dependence on
margin size, with a change of less than −0.5% per millimeter for both PAT and VMAT.
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While the relationship between ERR and margin size depended on risk model, the RRR
value did not appear to depend on margin size (figure 6) for any risk model considered. A
linear regression analysis revealed the change in RRR per millimeter was within 1% or less
per millimeter (interval: −0.004–0.009).

4. Discussion
We examined the dependence of the predicted risk of radiogenic second cancer on the
margin size around the CTV for PAT and VMAT for multiple risk models. We found that
the relationship between ERR and margin size depended on the risk model, with the linearnon-threshold model predicting the largest increase in risk with increasing margin size. The
RRR remained virtually constant with increasing margin, regardless of the risk model used.
Our results differ from those of Dasu et al (2011), who reported an approximately 50%
relative decrease in total risk of a radiogenic second cancer in the bladder and rectum with
decreasing margin size. However, in contrast with this work, their study used three-
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dimensional conformal radiotherapy and only two margin sizes: 10 mm posteriorly and 15
mm in all other anatomical directions and 4 mm posteriorly and 6 mm in all other
anatomical directions. The larger margin investigated by Dasu et al is outside the range
investigated in this study. Additionally, the risk model used in the work of Dasu et al
assumed a maximum risk for cancer induction at approximately 4 Gy, whereas the risk
models utilized in this work assumed a maximum risk for cancer induction at 10 Sv or 40 Sv
(in the models that modeled cell sterilization) or no maximum (in the linear-non-threshold
model). While we observed an increase in ERR with margin size for the linear-nonthreshold risk model, the effect was lessened with increasing consideration of cell
sterilization (that is, when using the linear-plateau and linear-exponential risk models), with
virtually no change in ERR related to margin size for the risk model that accounted for the
most cell sterilization (the linear-exponential risk model with an inflection point of 10 Sv).
This trend implies that one could expect a decrease in predicted risk with increasing margin
size when using a risk model that accounted for additional cell sterilization, such as the risk
model utilized by Dasu et al Given the differences in the modalities, risk models, and margin
sizes examined by the two studies, we do not consider the results of this study to conflict
with those of Dasu et al.
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The current results are significant because they clarify the robustness of the major finding of
our previous study, which compared the risks of radiogenic second cancer after PAT and
VMAT for prostate cancer (Rechner et al 2012). Specifically, we have now determined that
RRR is insensitive to margin size. Therefore, the results of our comparative risk study will
continue to be relevant if, in the future, margin sizes are decreased owing to anticipated
future improvements in beam localization and patient immobilization.
A strength of this study was the high levels of clinical realism and physical completeness of
by its intricate methodology, that is, the calculation of patient-specific therapeutic and stray
dose calculations. Furthermore, we tested several plausible relationships between dose and
risk of second cancer; the qualitative findings did not depend on the selection of risk model.
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This work’s few limitations are, we believe, mitigated by its comparative nature. For
example, we only calculated stray dose for the plans with the SOC margins and then
assumed that stray dose would be the same for all other plans for that modality. However,
since the same assumption was made for both modalities and a ratio of risks was calculated,
we consider this limitation to be minor. Additionally, while we expect the results of this
study to be applicable to similar comparative risk studies for prostate cancer, other sites may
have drastically different relationships between the risk of a second cancer and margin size,
depending on the nearby anatomy and the radiosensitivity of the organs at risk. Future
studies to investigate the effect of margin size on comparative risk for second cancers at
other treatment sites are clearly indicated.
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Figure 1.

Axial images showing sample PAT treatment plans with various CTV-to-PTV margins: (A)
0 mm in all directions, (B) 2 mm posteriorly and 4 mm in other directions, and (C) 6 mm
posteriorly and 8 mm in other directions. The rectum is shown in green, the CTV in cyan,
the PTV in white, and the prescribed isodose line (76 Gy (RBE)) in red.
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Figure 2.

Axial images showing sample VMAT treatment plans with various CTV-to-PTV margins:
(A) 0 mm in all directions, (B) 2 mm posteriorly and 4 mm in other directions, and (C) 6
mm posteriorly and 8 mm in other directions. The rectum is shown in green, the CTV in
cyan, the PTV in white, and the prescribed isodose line (76 Gy) in red.
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Figure 3.

Cumulative DVHs (cumulative volume as a function of dose) for the bladder wall and rectal
wall for all the PAT treatment plans created for this study, where the plan indices
correspond to those in table 1 (plan 1 has the smallest margin and plan 6 the largest).

NIH-PA Author Manuscript
Phys Med Biol. Author manuscript; available in PMC 2013 December 07.

Rechner et al.

Page 11

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 4.

Cumulative DVHs (cumulative volume as a function of dose) for the bladder wall and rectal
wall for all the VMAT treatment plans created for this study, where the plan indices
correspond to those in table 1 (plan 1 has the smallest margin and plan 6 the largest).
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Figure 5.

NIH-PA Author Manuscript

Plot of ERR versus CTV-to-PTV margin size for VMAT and PAT for all risk models
studied. A linear regression is shown for the most extreme cases to illustrate the range of
slopes resulting from the various risk models. The positive slope is largest for the linearnon-threshold model, but slope declines to approximately zero for the linear-exponential
model with an inflection point of 10 Gy. LNT, Lexp10, Lexp40, Lplat10, and Lplat40
denote the linear-non-threshold, linear-exponential and linear-plateau risk models with
inflection points at 10 Sv and 40 Sv, respectively.
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Figure 6.
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Plot of RRR versus CTV-to-PTV margin size for all risk models studied. A linear regression
is shown for the most extreme cases to illustrate the range of slopes resulting from the
various risk models. The positive slope is largest for the linear-non-threshold model, but the
slope declines to approximately zero for the linear-exponential model with an inflection
point of 10 Gy. LNT, Lexp10, Lexp40, Lplat10, and Lplat40 denote the linear-nonthreshold, linear-exponential and linear-plateau risk models with inflection points at 10 Sv
and 40 Sv, respectively.
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CTV-to-PTV margins and their difference from the current SOC margins at our institution for each treatment plan studied.
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Rectal Wall

Bladder Wall

Volume

78.9

Dmax

0.0

0.0
20.8

Dmin

79.4

Dmax

Dmean

79.9

10.5

Dmean

79.2

22.4

11.9

0.0

0.0

Dmin

Plan 2

Plan 1 (smallest margin)

Statistic

79.6

25.2

0.0

80.0

13.4

0.0

Plan 3

79.7

26.6

0.0

80.0

14.0

0.0

Plan 4

79.8

27.8

0.0

80.1

14.8

0.0

Plan 5

79.8

29.1

0.0

80.2

15.6

0.0

SOC Plan

PAT Therapeutic Dose (Gy (RBE))

79.9

30.3

0.0

80.3

16.2

0.0

Plan 6 (Largest Margin)

Minimum, mean, and maximum therapeutic doses (Dmin, Dmean, Dmax, respectively) in Gy (RBE) for each PAT treatment plan studied. Plan indices
correspond to those in table 1.
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Rectal Wall

Bladder Wall

Volume

80.0

Dmax

1.2

1.1
18.3

Dmin

82.3

Dmax

Dmean

81.0

11.3

Dmean

80.0

20.5

13.3

0.7

0.7

Dmin

Plan 2

Plan 1 (smallest margin)

Statistic

80.0

21.9

1.3

80.8

14.8

0.8

Plan 3

79.9

22.3

1.3

81.0

14.9

0.9

Plan 4

80.1

22.7

1.4

81.7

15.2

0.9

Plan 5

80.4

23.8

1.5

80.8

16.4

0.9

SOC Plan

VMAT Therapeutic Dose (Gy)

81.4

24.8

1.5

81.5

17.0

1.0

Plan 6 (Largest Margin)

Minimum, mean, and maximum therapeutic doses (Dmin, Dmean, Dmax, respectively) in Gy for each VMAT treatment plan studied. Plan indices
correspond to those in table 1.
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